{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:29:10Z","timestamp":1789532950787,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s11239-018-1647-9","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T10:23:19Z","timestamp":1521627799000},"page":"81-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael F.","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"issue":"6","key":"1647_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. New Engl J Med 325(6):393\u2013397. \n                    https:\/\/doi.org\/10.1056\/NEJM199108083250604","journal-title":"New Engl J Med"},{"issue":"3","key":"1647_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/jth.12114","volume":"11","author":"JP Westwood","year":"2013","unstructured":"Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M (2013) Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 11(3):481\u2013490. \n                    https:\/\/doi.org\/10.1111\/jth.12114","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1647_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3816\/CLML.2010.n.069","volume":"10","author":"S O\u2019Brien","year":"2010","unstructured":"O\u2019Brien S, Osterborg A (2010) Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 10(5):361\u2013368. \n                    https:\/\/doi.org\/10.3816\/CLML.2010.n.069","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"1647_CR4","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/trf.14193","volume":"57","author":"L Uhl","year":"2017","unstructured":"Uhl L, Kiss JE, Malynn E, Terrell DR, Vesely SK, George JN (2017) Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. Transfusion 57(10):2532\u20132538. \n                    https:\/\/doi.org\/10.1111\/trf.14193","journal-title":"Transfusion"},{"issue":"11","key":"1647_CR5","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","volume":"52","author":"F Beloncle","year":"2012","unstructured":"Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pene F, Mira JP, Galicier L, Guidet B, Baudel JL, Subra JF, Tanguy-Schmidt A, Pourrat J, Azoulay E, Veyradier A, Coppo P, Thrombotic Microangiopathies Reference C (2012) Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience. Transfusion 52 (11):2436\u20132444. \n                    https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03578.x","journal-title":"Transfusion"},{"issue":"5","key":"1647_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1600-0609.2007.00832.x","volume":"78","author":"HN Ahmad","year":"2007","unstructured":"Ahmad HN, Thomas-Dewing RR, Hunt BJ (2007) Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura. Eur J Haematol 78(5):449\u2013452. \n                    https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00832.x","journal-title":"Eur J Haematol"},{"issue":"1","key":"1647_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2141.2006.06384.x","volume":"136","author":"SR Cataland","year":"2007","unstructured":"Cataland SR, Jin M, Ferketich AK, Kennedy MS, Kraut EH, George JN, Wu HM (2007) An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 136(1):146\u2013149. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06384.x","journal-title":"Br J Haematol"},{"issue":"1","key":"1647_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/ejh.12206","volume":"92","author":"T Balen van","year":"2014","unstructured":"van Balen T, Schreuder MF, de Jong H, van de Kar NC (2014) Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol 92(1):80\u201382. \n                    https:\/\/doi.org\/10.1111\/ejh.12206","journal-title":"Eur J Haematol"},{"issue":"23","key":"1647_CR9","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","volume":"1","author":"SR Cataland","year":"2017","unstructured":"Cataland SR, Kourlas PJ, Yang S, Geyer S, Witkoff L, Wu H, Masias C, George JN, Wu HM (2017) Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. Blood Adv 1(23):2075\u20132082. \n                    https:\/\/doi.org\/10.1182\/bloodadvances.2017009308","journal-title":"Blood Adv"},{"issue":"1","key":"1647_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMc1714146","volume":"378","author":"MP Crowley","year":"2018","unstructured":"Crowley MP, McDonald V, Scully M (2018) Ofatumumab for TTP in a patient with anaphylaxis associated with rituximab. New Engl J Med 378(1):92\u201393","journal-title":"New Engl J Med"},{"issue":"5","key":"1647_CR11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","volume":"35","author":"GW Imhoff van","year":"2017","unstructured":"van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigon MDC, Ogura M, Leppa S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A (2017) Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol 35(5):544\u2013551. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.69.0198","journal-title":"J Clin Oncol"},{"issue":"13","key":"1647_CR12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","volume":"16","author":"MH Oers van","year":"2015","unstructured":"van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD, Gupta I, Phillips J, Williams V, Manson S, Lisby S, Geisler C, Investigators Ps (2015) Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 16(13):1370\u20131379. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00143-6","journal-title":"Lancet Oncol"},{"issue":"7","key":"1647_CR13","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","volume":"118","author":"M Scully","year":"2011","unstructured":"Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ (2011) A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 118(7):1746\u20131753. \n                    https:\/\/doi.org\/10.1182\/blood-2011-03-341131","journal-title":"Blood"},{"issue":"24","key":"1647_CR14","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","volume":"127","author":"EE Page","year":"2016","unstructured":"Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN (2016) Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood 127(24):3092\u20133094. \n                    https:\/\/doi.org\/10.1182\/blood-2016-03-703827","journal-title":"Blood"},{"issue":"2","key":"1647_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","volume":"124","author":"M Hie","year":"2014","unstructured":"Hie M, Gay J, Galicier L, Provot F, Presne C, Poullin P, Bonmarchand G, Wynckel A, Benhamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, Hamidou M, Vernant JP, Veyradier A, Coppo P, French Thrombotic Microangiopathies Reference C (2014) Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 124 (2):204\u2013210. \n                    https:\/\/doi.org\/10.1182\/blood-2014-01-550244","journal-title":"Blood"},{"issue":"24","key":"1647_CR16","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1182\/blood-2016-04-710475","volume":"127","author":"A Cuker","year":"2016","unstructured":"Cuker A (2016) Adjuvant rituximab to prevent TTP relapse. Blood 127(24):2952\u20132953. \n                    https:\/\/doi.org\/10.1182\/blood-2016-04-710475","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-018-1647-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1647-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1647-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T20:54:19Z","timestamp":1553115259000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-018-1647-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1007\/s11239-018-1647-9","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"21 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Al-Samkari, H: Consultancy (Agios Pharmaceuticals); Grace, R: Research Funding, Consultancy, Scientific Advisory Board (Agios Pharmaceuticals); Connors, JM: (Boehringer Ingelheim: Scientific Advisory Board; Bristol-Myers Squibb: Scientific Advisory Board, Consultant, Independent Review Committee; Unum Therapeutics: Data Safety Monitoring Board).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}}]}}